Japan Lifeline (7575) Q3 2026 earnings summary

Executive summary

• Net sales for 9M FY2026 reached a record ¥44,405mn, up 3.7% year-over-year, driven by increased procedure volumes and expansion in new therapeutic areas.

• Operating profit declined 0.8% year-over-year to ¥9,824mn, and net income fell 3.5% to ¥6,821mn, impacted by one-time costs, discontinued products, and HQ relocation expenses.

• Performance was in line with initial guidance for sales and operating profit, but net income was slightly below due to extraordinary losses.

• No revision to full-year financial guidance; Q4 is on track to meet plan, with a year-end dividend forecast of ¥54 per share (+¥1 YoY).

Financial highlights

• Gross profit margin for 9M FY2026 was 59.7%, down 80bps year-over-year; operating margin was 22.1%, down 100bps.

• Q3 FY2026 saw record sales (¥15,120mn, +2.0% YoY), but net income dropped 22.4% year-over-year due to increased SG&A and extraordinary losses.

• Proprietary product sales mix decreased to 55.5% (down 210bps), while procured product sales rose, especially in neurovascular and hemostatic devices.

• Basic EPS for 9M FY2026 was ¥97.25, down 2.1% year-over-year.

• Ordinary profit fell 3.4% to ¥9,608mn, impacted by non-operating expenses related to discontinued products.

Outlook and guidance

• Full-year forecast for FY ending March 31, 2026, maintained: net sales ¥59,300mn (+4.8% YoY), operating profit ¥12,900mn (+4.7%), net income ¥9,350mn (+0.3%), and EPS ¥133.30.

• Sales and operating profit are in line with initial guidance; net income slightly below due to one-time costs.

• Medium-term plan targets 7–8% average net sales growth and 5–6% operating profit growth over the next three years, with a final FY2028 net sales target of ¥70bn and OP margin at the 20% level.

• Growth strategies focus on maintaining dominance in core businesses, expanding new therapeutic areas, and accelerating global expansion.